登录新浪财经APP 搜索【信披】查看更多考评等级 证券日报网讯 1月27日,华东医药在互动平台回答投资者提问时表示,HDM1002作为具有差异化的口服GLP-1靶向药物,其定位正是为了满足全球市场未满足和差异化的临床需求。公司始终秉持开放合作战略,在强化自主研发的同时,积极与全球同行一起探索创新药管线的BD机会。未来如达成明确合作协议,公司将严格按照信息披露规则履行披露义务。(文章来源:证券日报)...
Source Link登录新浪财经APP 搜索【信披】查看更多考评等级 证券日报网讯 1月27日,华东医药在互动平台回答投资者提问时表示,HDM1002作为具有差异化的口服GLP-1靶向药物,其定位正是为了满足全球市场未满足和差异化的临床需求。公司始终秉持开放合作战略,在强化自主研发的同时,积极与全球同行一起探索创新药管线的BD机会。未来如达成明确合作协议,公司将严格按照信息披露规则履行披露义务。(文章来源:证券日报)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.